-
公开(公告)号：EP3066131A1
公开(公告)日：2016-09-14
申请号：EP14810051.4
申请日：2014-11-07
发明人： SCHEINBERG, David , VEOMETT, Nicholas , LIU, Hong , XIANG, Jingyi , LIU, Cheng , DAO, Tao , HUET, Heather, Adkins
IPC分类号： C07K16/32 , A61K39/395 , A61P35/00 , A61P35/02 , A01K67/027
CPC分类号： C07K16/32 , A01K2227/105 , A01K2267/0387 , A61K2039/505 , C07K2317/21 , C07K2317/41 , C07K2317/72 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present disclosure relates to an anti-WT-1/HLA/A2 antibody with enhanced antibody dependent cell-mediated cytotoxicity (ADCC) function due to altered Fc glycosylation. The antibody, which has reduced fucose and/or galactose, was compared to its normally glycosylated counterpart in binding assays,
in vitro ADCC assays, and mesothelioma and leukemia therapeutic models and pharmacokinetic studies in mice. The antibody with normal glycosylation mediated ADCC against hematopoietic and solid tumor cells at concentrations below 1 μg/ml, but the reduced fucosylated antibody was about 5-10 fold more potent
in vitro against multiple cancer cell lines, was more potent
in vivo against JMN mesothelioma, and effective against SET2 AML and fresh ALL xenografts. ESKM had a shortened half-life (4.9
vs 6.5 days), but an identical biodistribution pattern in C57BL6/J mice. At therapeutic doses of ESKM, there was no difference in half-life or biodistribution in HLA-A2.1 + transgenic mice compared to the parent strain. Importantly, therapeutic doses of ESKM in these mice caused no depletion of total WBCs or hematopoetic stem cells, or pathologic tissue damage.-
2.发明公开T CELL RECEPTOR-LIKE ANTIBODY AGENTS SPECIFIC FOR EBV LATENT MEMBRANE PROTEIN 2A PEPTIDE PRESENTED BY HUMAN HLA 审中-公开T细胞受体样抗体特异性EBV潜伏膜蛋白2A肽由人类HLA呈递
公开(公告)号：EP3307319A2
公开(公告)日：2018-04-18
申请号：EP16808304.6
申请日：2016-06-09
发明人： CHEUNG, Nai-Kong V. , AHMED, Mahiuddin , LOPEZ-ALBAITERO, Andres , LIU, Cheng , LIU, Hong , XIANG, Jingyi , YAN, Su
IPC分类号： A61K39/395 , A61K39/42 , A61P31/22 , C07K16/08 , C07K16/28
CPC分类号： C07K16/468 , A61K2039/505 , A61K2039/572 , C07K16/085 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/40 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/92 , G01N33/6854
摘要： Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.
-
公开(公告)号：EP3066130B1
公开(公告)日：2019-05-15
申请号：EP14803300.4
申请日：2014-11-07
发明人： SCHEINBERG, David , XIANG, Jingyi , DAO, Tao , YAN, Su , LIU, Cheng
-
公开(公告)号：EP3066130A1
公开(公告)日：2016-09-14
申请号：EP14803300.4
申请日：2014-11-07
发明人： SCHEINBERG, David , XIANG, Jingyi , DAO, Tao , YAN, Su , LIU, Cheng
CPC分类号： C07K16/32 , A61K2039/505 , C07K16/2809 , C07K2317/31 , C07K2317/34 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2317/94 , C07K2319/00
摘要： Disclosed herein is a bi-specific form of a T cell receptor mimic (TCRm) mAb with reactivity to human immune effector cell antigen and a WT1 peptide/HLA-A epitope. This antibody selectively bound to leukemias and solid tumor cells expressing WT1 and HLA-A as well as activated resting human T cells to release interferon- (IFN-γ) and to kill the target cancer cells in vitro. Importantly, the antibody mediated autologous T cell proliferation and directed potent cytotoxicity against fresh ovarian cancer cells. Therapeutic activity in vivo of the antibody was demonstrated in NOD SCID SCID Yc* (NSG) mice with three different human cancers expressing WT1 /HLA-A2 including disseminated Ph+ acute lymphocytic leukemia (ALL), disseminated acute myeloid leukemia, and peritoneal mesothelioma. In both of the leukemia xenograft models, mice that received the antibody and T cells also showed longer survival and delayed limb paralysis. Also provided are methods for stimulating a primary T cell response comprising stimulating cytotoxic T cells against a first tumor antigen and a secondary T cell response comprising stimulating effector T cells and/or memory T cells against a first tumor antigen and/or against a second tumor antigen using the bi-specific antibodies described herein.
-
公开(公告)号：EP3579879A1
公开(公告)日：2019-12-18
申请号：EP18752019.2
申请日：2018-02-06
发明人： HSU, Katharine , CHEUNG, Nai-Kong V. , YAN, Su , XU, Yiyang , XIANG, Jingyi , LIU, Cheng
IPC分类号： A61K39/395 , A61K39/00
-
公开(公告)号：EP2340305A1
公开(公告)日：2011-07-06
申请号：EP09790694.5
申请日：2009-07-21
发明人： LIU, Cheng , XIANG, Jingyi , YAN, Su , WANG, Pei , TAI, Wei, Chan
CPC分类号： C07K16/18 , C07K2317/73 , C07K2317/732 , C12N9/1048 , C12P21/005
摘要： The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value.
-
公开(公告)号：EP3325517A2
公开(公告)日：2018-05-30
申请号：EP16828666.4
申请日：2016-07-22
发明人： LIU, Hong , XIANG, Jingyi , XU, Yiyang , CHAN, Vivien, Wai-Fan
IPC分类号： C07K19/00 , C07K16/18 , A61K39/395
CPC分类号： C07K16/2833 , C07K16/3069 , C07K2317/21 , C07K2317/32
摘要： The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising a PSA peptide and an MHC class I protein. Also provided are methods of making and using these constructs.
-
公开(公告)号：EP3615574A1
公开(公告)日：2020-03-04
申请号：EP18791195.3
申请日：2018-04-24
发明人： ZHANG, Pengbo , XU, Yiyang , MORALES, Javier , NAKANO, Yoko , LIU, Hong , XIANG, Jingyi , ACKER, Timothy
IPC分类号： C07K16/30 , C07K16/46 , C07K19/00 , G01N33/574 , A61K39/395 , A61P35/00
-
9.发明公开CONSTRUCTS TARGETING NY-ESO-1 PEPTIDE/MHC COMPLEXES AND USES THEREOF 审中-公开靶向NY-ESO-1肽/ MHC复合物的构建体及其用途
公开(公告)号：EP3313873A2
公开(公告)日：2018-05-02
申请号：EP16815452.4
申请日：2016-06-24
发明人： LIU, Cheng , LIU, Hong , XU, Yiyang , XIANG, Jingyi
IPC分类号： C07K14/705 , A61K39/395 , G01N33/574
CPC分类号： G01N33/57492 , C07K14/00 , C07K14/4748 , C07K16/2809 , C07K16/2833 , C07K16/3069 , C07K2317/21 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/03 , G01N2333/70539
摘要： The present application provides constructs comprising an antibody moiety that specifically binds to a complex comprising an NY-ESO-1 peptide and an MHC class I protein. Also provided are methods of making and using these constructs.
-
公开(公告)号：EP3297671A2
公开(公告)日：2018-03-28
申请号：EP16797161.3
申请日：2016-05-17
发明人： WONG, Brian , MASTELLER, Emma , LIU, Cheng , XU, Yiyang , LIU, Hong , YAN, Su , XIANG, Jingyi , WANG, Pei
IPC分类号： A61K39/395 , C07K16/28 , C12N1/15 , C12N1/21 , G01N33/574
CPC分类号： C07K16/2803 , A61K38/05 , A61K47/6817 , A61K47/6851 , A61K47/6881 , A61K51/1027 , A61K51/1042 , A61K51/1096 , A61K2039/505 , A61P35/00 , A61P35/02 , C07K16/005 , C07K16/2809 , C07K16/30 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2319/00 , G01N33/57492 , G01N2333/912
摘要： The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof, for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.021 秒)
